Back to Schemes

New!

Myeloid Panel

Product Code: 09-MYP-27

From £545.00

Deadline to order: 01/03/2027

NGS panel testing for myeloid malignancies (AML, MPN and MDS)

Target/Genes:

Myeloid NGS panel testing for the assessment of myeloid malignancies, including acute myeloid leukaemia (AML), myeloproliferative neoplasms (MPN), and myelodysplastic syndromes (MDS). Testing may be performed using any appropriate NGS gene panel for myeloid malignancies.

Technology:

NGS, Panel testing

Language:

English, French, German, Italian, Spanish

Sample Type:

DNA (in TE Buffer)

Accredited:

No

Sample dispatch to your laboratory:

To be finalised

Test and Submit Results:

To be finalised (for exact dates, please see scheme instructions)

Final Results and Certificate:

To be finalised (for exact dates, please see scheme instructions)

You can complete purchase on our secure partner site.

How it works

Register

  • Enrol before the closing date (01/03/2027)
  • EMQN ships EQA samples or digital cases

Test & submit results

  • Analyse samples in your routine workflow
  • Upload results via your website account (To be finalised (for exact dates, please see scheme instructions))

Review & get certified

  • EMQN assesses your data
  • Receive your individual results, EQA summary report & certificate of participation (To be finalised (for exact dates, please see scheme instructions))

EQA Assessment

The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.

Sample Details

Three mock clinical cases will be provided with corresponding DNA samples for analysis, interpretation and reporting.

Approximately 1.0-2.0µg DNA per sample is provided. Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

Panel testing can be performed using any appropriate gene panel for myeloid malignancies. To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment. Only variants that have been validated in the test samples will be assessed.

No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).

Enquire about this scheme

Contact Information

added wishlist!
View Wishlist

0

View Wishlist

Register Interest

Express your interest in ''.